Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03828019
Other study ID # 9196
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date September 16, 2019
Est. completion date September 17, 2024

Study information

Verified date November 2023
Source JHSPH Center for Clinical Trials
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Non-infectious intermediate, posterior, and panuveitides are chronic, potentially-blinding diseases. Vision-threatening cases require long-term therapy with oral corticosteroids and immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNF-α monoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional immunosuppressive drugs. The ADVISE Trial is multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.


Description:

Abstract from protocol: The uveitides are a collection of diseases characterized by intraocular inflammation. Collectively, they are the 5th leading cause of blindness in the US, and the estimated cost of treating them is similar to that of treating diabetic retinopathy. Non-infectious intermediate, posterior, and panuveitides have the highest rates of visual loss and typically are treated with oral corticosteroids and immunosuppression. The Multicenter Uveitis Steroid Treatment (MUST) Trial (a randomized, comparative effectiveness trial, which compared 2 treatment paradigms for these diseases, systemic therapy with corticosteroids and immunosuppression vs. regional therapy [the fluocinolone acetonide implant]), and Follow-up Study demonstrated the superiority of the systemic approach to the regional ocular approach in terms of long-term visual outcomes with essentially no increase in systemic side effects in the systemic group. One key to systemic therapy's success was the use of systemic immunosuppression in 88% of participants, coupled with tapering the prednisone to <7.5 mg/day, a relatively safe dose. Non-alklyating agents are typically the first choice and the most often used are azathioprine, methotrexate, mycophenolate, cyclosporine, and tacrolimus. The alkylating agents, cyclophosphamide and chlorambucil, are used less often because of concerns about potential increased malignancy risk. Data from the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study suggest that each of the conventional, non-alkylating agent immunosuppressive drugs is effective in controlling the inflammation while permitting tapering prednisone in ~40-55% of patients; hence combination therapy often is needed. Furthermore, minimizing the daily dose of prednisone is important, as the risk of cardiovascular disease and mortality increase with the cumulative dose of oral corticosteroids. In June 2016, the fully-human, anti-TNF-α monoclonal antibody, adalimumab, was approved by the US Food and Drug Administration (FDA) for the treatment of uveitis. Anti-TNF-α monoclonal antibody therapy has revolutionized the management of the rheumatic diseases largely due to its superior efficacy compared to conventional Disease Modifying Anti-Rheumatic Drugs. Data from VISUAL III, the extension of the two phase 3 trials that led to the FDA approval of adalimumab for the treatment of uveitis, suggest that adalimumab may be superior to conventional immunosuppression, as ~75% of participants had controlled inflammation with prednisone doses <5 mg/day. The ADalimumab Vs. conventional ImmunoSupprEssion for uveitis (ADVISE) Trial is a randomized, comparative effectiveness trial comparing adalimumab to conventional agent immunosuppression for patients with non-infectious, intermediate, posterior, and panuveitides. The primary outcome is the ability to successfully taper prednisone to <7.5 mg/day by 6 months after randomization while maintaining control of the inflammation. Secondary outcomes include prednisone discontinuation by 1 year, visual acuity, and complications of uveitis and its treatment. ADVISE is being conducted under IND 132532. Adalimumab was FDA approved for the treatment of non-infectious intermediate, posterior, and panuveitides in adult patients in 2016 and in pediatric patients 2 years of age and older in 2018. In 2016, prior to the approval for pediatric patients, the FDA determined that use of adalimumab for the treatment of non-infectious intermediate, posterior, and panuveitides in adolescent patients in the ADVISE Trial does not increase risk for these patients as the drug is approved for treatment of pediatric patients for other indications. Although conventional immunosuppressive drugs are the standard approach and in widespread use, these drugs are not FDA approved for treatment of non-infectious intermediate, posterior, and panuveitides, and therefore an IND has been issued for this trial.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 222
Est. completion date September 17, 2024
Est. primary completion date April 12, 2024
Accepts healthy volunteers No
Gender All
Age group 13 Years and older
Eligibility Inclusion criteria 1. Age 13 years or older 2. Weight 30 kg (66 lbs) or greater 3. Active or recently active (= 60 days) non-infectious intermediate, posterior, or panuveitis 4. Prednisone indication meets one of the following: 1. Active uveitis requiring one of the following i. Initiation of prednisone at dose greater than 7.5 mg/day ii. Increasing prednisone dose to greater than 7.5 mg/day iii. Currently receiving dose greater than 7.5 mg/day 2. Inactive uveitis on current dose greater 7.5 mg/day 5. Initiation or addition of an immunosuppressive drug (i.e., a conventional immunosuppressive drug or adalimumab) is indicated 6. If currently receiving a conventional immunosuppressive drug, the drug and dose have been stable for at least 30 days 7. Patient able and willing to self-administer subcutaneous injections or have a qualified person available to administer subcutaneous injections 8. If posterior segment disease is present, ability to assess activity in at least one eye with uveitis 9. Visual acuity of light perception or better in at least one eye with uveitis Exclusion criteria 1. Active tuberculosis or untreated latent tuberculosis (e.g., positive interferon-? release assay [IGRA] test, such as Quantiferon-gold) 2. Untreated active hepatitis B or C infection 3. Any of the following baseline lab values 1. White blood count <3500 cells per microliter 2. Platelets <100,000 per microliter 3. Hematocrit <30% 4. AST or ALT >1.5X upper limit normal value 5. Serum creatinine >1.1X upper limit normal value 4. Behçet disease 5. Multiple sclerosis or other demyelinating disease 6. For patients with anterior/intermediate or intermediate uveitis without systemic disease, abnormal magnetic resonance imaging (MRI) of the brain consistent with demyelinating disease 7. Severe uncontrolled infection 8. Receipt of a live vaccine within past 30 days 9. Moderate to severe heart failure (NYHA class III/IV) 10. Active malignancy 11. Use of anti-TNF monoclonal antibody therapy within past 60 days 12. History of adalimumab intolerance or ineffectiveness 13. Hypersensitivity to any of the study treatments or their excipients 14. Current treatment with an alkylating agent 15. Current treatment with more than one immunosuppressive drug, not including oral corticosteroids 16. Shorter-acting regional corticosteroids administered within the past 30 days in any eye(s) with uveitis 17. Long-acting ocular corticosteroid implants, i.e., fluocinolone acetonide implant (e.g., Retisert®, YutiqTM, Iluvien®) placed within past 3 years unless uveitis is active in all eye(s) with an implant 18. Systemic disease that is sufficiently active such that it dictates therapy with systemic corticosteroids or immunosuppressive agents at the time of enrollment 19. Immunodeficiency disease for which immunosuppressive therapy would be contraindicated according to best medical judgment 20. Pregnancy or lactation 21. For persons of child-bearing potential or impregnating potential, unwillingness to use appropriate birth control (abstinence, combination barrier and spermicide, hormonal, or intrauterine device) for the next 18 months or plans to become a biological parent within the next 18 months. * In the UK, use of combination barrier and spermicide alone does not meet birth control requirements. † UK female study participants must use highly effective methods of contraception. UK male study participants must use condoms for at least 6 months after the end of study treatment and their female partners of child-bearing potential are recommended to use highly effective contraception for the same duration. In addition, male participants should not donate semen during therapy or for 6 months following discontinuation of study treatment. 22. Medical problems or drug or alcohol dependence problems sufficient to prevent adherence to treatment and study procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Adalimumab (ADA)
Adalimumab is a fully-human monoclonal antibody to TNF-a, which is approved by the U.S. FDA for the treatment of non-infectious intermediate, posterior, and panuveitides in adults and children 2 years of age and older.
Drug:
Conventional immunosuppression (CON)
The study ophthalmologist will select amongst the permissible drugs (methotrexate, mycophenolate mofetil or azathioprine for antimetabolites; cyclosporine or tacrolimus for calcineurin inhibitors) taking into account the side effect profile of each drug with respect to subject's clinical situation.

Locations

Country Name City State
Australia Centre for Eye Research Australia East Melbourne Victoria
Australia University of Sydney Sydney
Canada McGill University Montréal Quebec
United Kingdom Bradford Teaching Hospital NHS Foundation Trust Bradford
United Kingdom Cambridge University NHS Trust Cambridge
United Kingdom University Hospital Birmingham Edgbaston Birmingham
United Kingdom University Hospitals of Leicester Leicester
United Kingdom Moorfields Eye Hospital NHS Foundation Trust London
United States University of Michigan Health System, Kellogg Eye Center Ann Arbor Michigan
United States Emory University Atlanta Georgia
United States Johns Hopkins University Baltimore Maryland
United States Retinal Consultants of Texas Bellaire Texas
United States National Eye Institute Bethesda Maryland
United States Ophthalmic Consultants of Boston Boston Massachusetts
United States Northwestern University Chicago Illinois
United States Rush University Medical Center Chicago Illinois
United States University of Iowa Iowa City Iowa
United States Jules Stein Eye Institute, UCLA Los Angeles California
United States Anne Bates Leach Eye Hospital, University of Miami Miller School of Medicine Miami Florida
United States Tennessee Retina Nashville Tennessee
United States Vanderbilt University Eye Institute Nashville Tennessee
United States MidAtlantic Retina, Wills Eye Hospital Philadelphia Pennsylvania
United States University of Pennsylvania Philadelphia Pennsylvania
United States University of Pittsburgh Medical Center Pittsburgh Pennsylvania
United States Washington University Saint Louis Missouri
United States University of Utah, Moran Eye Center Salt Lake City Utah
United States University of California, San Francisco San Francisco California
United States University of Washington, Medicine Eye Institute Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
JHSPH Center for Clinical Trials

Countries where clinical trial is conducted

United States,  Australia,  Canada,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Corticosteroid-sparing treatment success within the first 6 months after randomization Corticosteroid-sparing success is defined as achieving inactive uveitis for two consecutive visits >= 28 days apart while on <= 7.5 mg/day of corticosteroids. Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging. 6 months
Secondary Corticosteroid-sparing treatment success within the first 12 months after randomization Corticosteroid-sparing success is defined as achieving inactive uveitis for two consecutive visits >= 28 days apart while on <= 7.5 mg/day of corticosteroids. Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging. 12 months
Secondary Prednisone discontinuation success Prednisone discontinuation success is defined as achieving inactive uveitis for two consecutive visits >= 28 days apart after discontinuing corticosteroids. Uveitis status (active vs inactive) is determined by the study ophthalmologist after reviewing the eye exam and imaging. 12 months
Secondary Prednisone exposure E.g., cumulative prednisone dose and/or mean prednisone dose 12 months
Secondary Best corrected visual acuity Best corrected visual acuity measured after a standardized refraction using logarithmic visual acuity charts 12 months
Secondary Infections Incidence of infections over 12 months of follow-up 12 months
Secondary Systemic adverse events Systemic adverse events over 12 months of follow-up 12 months
Secondary Macular edema Macular edema over 12 months of follow-up 12 months
Secondary Health utility Health utility will be measured using the EQ-5D 12 months
Secondary Generic health-related quality of life Generic health-related quality of life will be measured using the SF-36 12 months
Secondary Vision-related quality of life Vision-related quality of life will be measured using the NEI-VFQ-25 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Active, not recruiting NCT04704609 - Imaging Quantification of Inflammation (IQI)
Completed NCT03173144 - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Withdrawn NCT01280669 - Intravitreal Sirolimus as Therapeutic Approach to Uveitis Phase 2
Terminated NCT02907814 - Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography N/A
Active, not recruiting NCT02252328 - Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients Phase 2/Phase 3
Completed NCT04183387 - Simvastatin in Uveitis Phase 2
Completed NCT01983488 - Clinical Outcome in Uveitis
Withdrawn NCT00499551 - A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Phase 1/Phase 2
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Completed NCT00132691 - Multicenter Uveitis Steroid Treatment (MUST) Trial Phase 4
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT00001867 - Effect of Pregnancy on Uveitis N/A
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Terminated NCT01939691 - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Phase 4
Active, not recruiting NCT03889860 - Objective Choroidal Thickness Measurements in Uveitis
Completed NCT00070759 - Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis Phase 2
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Active, not recruiting NCT05385757 - UNICORNS: Uveitis in Childhood Prospective National Cohort Study
Active, not recruiting NCT06260449 - Different Treatment Approaches of Presumed Trematode-Induced Uveitis N/A